Green nanotech paradigm for enhancing sesquiterpene lactone therapeutics in cancer

Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved..

In the field of cancer therapy, sesquiterpene lactones (SLs) derived from diverse Dicoma species demonstrate noteworthy bioactivity. However, the translation of their full therapeutic potential into clinical applications encounters significant challenges, primarily related to solubility, bioavailability, and precise drug targeting. Despite these obstacles, our comprehensive review introduces an innovative paradigm shift that integrates the inherent therapeutic properties of SLs with the principles of green nanotechnology. To overcome issues of solubility, bioavailability, and targeted drug delivery, eco-friendly strategies are proposed for synthesizing nanocarriers. Green nanotechnology has emerged as a focal point in addressing environmental and health concerns linked to conventional treatments. This progressive approach of green nanotechnology holds promise for the development of safe and sustainable nanomaterials, particularly in the field of drug delivery. This groundbreaking methodology signifies a pioneering advancement in the creation of novel and effective anticancer therapeutics. It holds substantial potential for transforming cancer treatment and advancing the landscape of natural product research.

Medienart:

E-Artikel

Erscheinungsjahr:

2024

Erschienen:

2024

Enthalten in:

Zur Gesamtaufnahme - volume:173

Enthalten in:

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 173(2024) vom: 26. März, Seite 116426

Sprache:

Englisch

Beteiligte Personen:

Zahra, Mehak [VerfasserIn]
Abrahamse, Heidi [VerfasserIn]
George, Blassan P [VerfasserIn]

Links:

Volltext

Themen:

Anticancer therapy
Bioactive compounds
Dicoma species
Green nanotechnology
Journal Article
Lactones
Review
Sesquiterpene lactones
Sesquiterpenes

Anmerkungen:

Date Completed 27.03.2024

Date Revised 27.03.2024

published: Print-Electronic

Citation Status MEDLINE

doi:

10.1016/j.biopha.2024.116426

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM369609921